VOLUME 12 NUMBER 9 SEPTEMBER 2011 nature immunology T lymphocytes are pivotal in adaptive immunity. Mature T cells circulate through the blood and peripheral lymphoid organs in a quiescent state (G0) characterized by small cell size and low metabolic activity. The survival of naive T cells relies on the engagement of T cell antigen receptors (TCRs) by self peptide presented on major histocompatibility complex and the interaction between interleukin 7 (IL-7) and its receptor [1] [2] [3] . As these signals can potentially result in inappropriate activation, T cell quiescence must be actively maintained [4] [5] [6] . Foxo and Klf2 transcription factors were thought to regulate T cell quiescence by inducing the expression of inhibitors of cellular activation 7-9 . However, evidence now suggests that they might not directly maintain the quiescent state; instead, they contribute to T cell homeostasis by regulating the survival and trafficking of T cells [10] [11] [12] [13] [14] [15] . Therefore, it remains poorly defined how quiescence is established in T cells and whether it is coordinately regulated with T cell survival.
T lymphocytes are pivotal in adaptive immunity. Mature T cells circulate through the blood and peripheral lymphoid organs in a quiescent state (G0) characterized by small cell size and low metabolic activity. The survival of naive T cells relies on the engagement of T cell antigen receptors (TCRs) by self peptide presented on major histocompatibility complex and the interaction between interleukin 7 (IL-7) and its receptor [1] [2] [3] . As these signals can potentially result in inappropriate activation, T cell quiescence must be actively maintained [4] [5] [6] . Foxo and Klf2 transcription factors were thought to regulate T cell quiescence by inducing the expression of inhibitors of cellular activation [7] [8] [9] . However, evidence now suggests that they might not directly maintain the quiescent state; instead, they contribute to T cell homeostasis by regulating the survival and trafficking of T cells [10] [11] [12] [13] [14] [15] . Therefore, it remains poorly defined how quiescence is established in T cells and whether it is coordinately regulated with T cell survival.
When naive T cells encounter cognate antigen, they undergo extensive clonal expansion and switch their metabolic program from catabolism to anabolism. Despite the presence of adequate amounts of oxygen in the environment, activated T cells use glycolysis to generate energy, a phenomenon known as the Warburg effect 16, 17 . The conserved serine-threonine kinase mTOR is a central regulator of glycolysis and cellular metabolism 18 . It exists in two multiprotein complexes in metazoans: mTORC1 and mTORC2. The mTORC1 complex contains the scaffolding protein Raptor and is partly sensitive to the immunosuppressant rapamycin. It promotes translational initiation by phosphorylating the kinase S6K and translation-initiation inhibitor 4E-BP1 and stimulates cell growth and metabolism. The activity of mTORC1 is stringently controlled by the tumor suppressors Tsc1 and Tsc2; mutations of the genes encoding Tsc1 and Tsc2 are found in hamartoma syndrome that involves tissue overgrowth. Tsc1 and Tsc2 function as an integral complex, and ablation of either Tsc1 or Tsc2 disrupts the complex 18 . The second mTOR complex, mTORC2, contains the distinct scaffolding protein Rictor and is important for activation of the kinase Akt by inducing phosphorylation at Ser473 and selective Akt targets such as Foxo proteins 18 . There is a considerable interaction between the two mTOR complexes, and activated mTORC1 institutes negative feedback loops to inhibit Akt 18 . An essential role is emerging for mTOR in both the innate and adaptive immune systems [19] [20] [21] . In T cells, mTOR is an important determinant of lineage differentiation after antigen stimulation, but whether it is involved in the homeostasis of naive T cells is unclear.
We report here that Tsc1 is a central regulator of the quiescence and homeostasis of naive T cells. Loss of quiescence predisposed Tsc1-deficient T cells to apoptotic death and prevented effective generation of an adaptive immune response. Our data point to a previously unknown checkpoint actively maintaining the quiescence of naive cells that affects immune homeostasis and function. Tsc1 deficiency resulted in more activity of mTORC1 but less activity of mTORC2-Akt. Our combined use of genetic models and pharmacological approaches indicates that Tsc1 regulates T cell homeostasis and function mainly by negative control of mTORC1 activity.
RESULTS

Tsc1 in the regulation of peripheral T cell populations
After engagement of the TCR, mTOR is activated, but how it is regulated in naive T cells is unclear. We found that Tsc1, a modulator of mTOR signaling, was expressed in thymic and peripheral naive T cells (Supplementary Fig. 1a-c) . To investigate the function of Tsc1 in T cells, we crossed mice with conditional expression of loxP-flanked Tsc1 alleles (Tsc1 flox/flox ) 22 with mice with transgenic expression of Cre recombinase from the Cd4 promoter to delete the loxP-flanked Tsc1 alleles specifically in T cells (called 'Tsc1 −/− mice' here). Analysis of mRNA and protein indicated efficient deletion of Tsc1 in mature thymocytes and peripheral T cells (Supplementary Fig. 1a-c) . Wild-type and Tsc1 −/− mice had similar numbers of total thymocytes as well as CD4 − CD8 − doublenegative, CD4 + CD8 + double-positive, CD4 + single-positive and CD8 + single-positive subsets (Fig. 1a) and had similar expression of thymocyte-maturation markers, including CD62L, CD69 and CD24 (Supplementary Fig. 1d ). In contrast, Tsc1 −/− mice had considerably fewer T cells in the spleen (Fig. 1b) , peripheral blood and lymph nodes and an altered ratio of CD4 + cells to CD8 + cells relative to that of their wild-type or heterozygous (Tsc1 +/− ) littermates ( Supplementary Fig. 1e-g ).
We next analyzed the distribution of various T cell subsets in the periphery of Tsc1 −/− mice. Among the conventional CD4 + and CD8 + T cell compartments, Tsc1 −/− mice had an expanded CD62L lo CD44 hi population with an activated or memory phenotype, with a correspondingly lower number of CD62L hi CD44 lo naive T cells (Fig. 1c) . This alteration was further exacerbated in older mice (Supplementary Fig. 2a ). Tsc1 deficiency did not seem to affect the homeostasis of regulatory T cells expressing the transcription factor Foxp3 (Supplementary Fig. 2b ). In contrast, the spleens and livers of Tsc1 −/− mice had fewer invariant natural killer T cells (iNKT cells), as detected by a tetramer of the antigen-presenting molecule CD1d and the α-galactosylceramide analog PBS57 ( Fig. 1d and Supplementary  Fig. 2c ). Tsc1 is thus crucial for maintaining the peripheral populations of conventional T cells and iNKT cells.
To address whether the smaller peripheral T cell pool in Tsc1 −/− mice was a cell-autonomous defect, we generated mixed-bone marrow chimeras by reconstituting mice deficient in recombination-activating gene 1 with a 1:1 mixture of wild-type or Tsc1 −/− (CD45.2 + ) bone marrow cells and wild-type (CD45.1 + ) bone marrow cells. Populations of Tsc1 −/− donor cells in the reconstituted chimeras had fewer CD4 + and CD8 + T cells than did those derived from wild-type donor bone marrow and retained the higher ratio of CD4 + cells to CD8 + cells (Fig. 1e) . We also found fewer iNKT cells in the mixed chimeras (data not shown). We conclude that Tsc1 exerts a cell-autonomous function in maintaining peripheral T cell populations.
Tsc1 promotes the survival of peripheral T cells
The overall size of the peripheral T cell pool is dependent on T cell survival [1] [2] [3] . We therefore measured caspase activity, a hallmark of apoptotic cell death. Tsc1 −/− T cells had more caspase activity than did wild-type control cells, and this was more prominent in CD8 + T cells (Fig. 2a) . In contrast, mature thymocytes from wild-type and Tsc1 −/− mice had similar caspase activity (data not shown). Mitochondrial homeostasis is critical for the regulation of apoptosis, and loss of mitochondrial membrane potential is a general feature of apoptosis 23 . Tsc1 −/− T cells had less mitochondria content and lower mitochondrial transmembrane potential, as shown by staining with mitochondriaspecific dyes 24 (Supplementary Fig. 3 ). Therefore, deficiency in Tsc1 induces apoptosis of peripheral T cells.
We next evaluated the survival ability of Tsc1-deficient T cells in vivo. We adoptively transferred a mixture of equal numbers of CD45.2 + wild-type or Tsc1 −/− donor T cells (labeled with the cytosolic dye CFSE) and CD45.1 + ('spike') T cells into CD45.2 + recipient mice. The 'spike' group served as an internal control for normalization, and we used sorted naive T cells (CD62L hi CD44 lo CD25 − ) to obviate the altered homeostasis that developed in Tsc1 −/− mice. In contrast to wild-type donor cells, which were well maintained after transfer, Tsc1-deficient cells were rapidly lost and essentially undetectable (Fig. 2b) . We observed similar changes in the spleen, lymph nodes ( Fig. 2b ) and blood (data not shown), which indicated that the disappearance of Tsc1 −/− cells was not caused by altered trafficking 25 . The presence of a normal lymphocyte pool in the recipients prevented the proliferation of donor cells in the time interval assessed. Therefore, the disappearance of Tsc1-deficient T cells was most probably due to a defect in survival in vivo. We then determined the intrinsic requirement for Tsc1 in the survival of naive T cells by examining IL-7 signaling 2,3 . We cultured sorted naive T cells from wild-type or Tsc1 −/− mice with IL-7 for 3 d. Tsc1 −/− cells were much less responsive to IL-7-triggered survival effects than were wild-type cells (Fig. 2c) . The expression of the IL-7 receptor α-chain was similar in wild-type and Tsc1 −/− cells (Fig. 2c) , which suggested that the defective response to IL-7 was not due to impaired expression of its receptor. These findings demonstrate that Tsc1 −/− cells are defective in response to homeostatic cytokine signals in vitro.
To further understand the peripheral T cell deficiency observed in Tsc1 −/− mice, we stimulated naive wild-type and Tsc1 −/− T cells with antibody to CD3 (anti-CD3), anti-CD3 plus anti-CD28, or a combination of phorbol 12-myristate 13-acetate (PMA) and ionomycin. At 16 h, whereas only a small subset of wild-type cells died (as indicated by their positive staining with propidium iodide), most of the Tsc1 −/− T cells had become propidium iodide positive (Fig. 2d) . Kinetic analysis showed that Tsc1 −/− cells had accelerated death after 6 h of TCR stimulation, with CD8 + T cells progressing slightly faster than CD4 + T cells (Fig. 2e) . T cells can die via both apoptotic and necrotic pathways 1 . Treatment with the antiapoptotic compound z-VAD-fmk attenuated the death of Tsc1 −/− cells (Fig. 2f) . In contrast, treatment with necrostatin-1 to block necrotic death had no noticeable effect (data not shown). Therefore, Tsc1 −/− cells respond to TCR signals by undergoing extensive apoptotic death.
Tsc1 −/− T cells die via the intrinsic apoptotic pathway Apoptosis of T cells is mediated by the intrinsic apoptotic pathway (controlled by the balance of pro-and antiapoptotic members of the Bcl-2 family) and the extrinsic pathway (controlled by signals delivered from death receptors such as Fas) [1] [2] [3] . Fas expression was similar in wildtype and Tsc1 −/− T cells (data not shown). We therefore focused on the intrinsic pathway and found that Bcl-2 expression was downregulated 
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in Tsc1 −/− T cells (Fig. 3a) . We further examined this by crossing Tsc1 −/− mice with mice expressing a Bcl2 transgene in lymphocytes (Bcl2-transgenic mice) 26 . The number of CD4 + T cells and CD8 + T cells, as well as iNKT cells, was nearly completely restored in Tsc1 −/− Bcl2-transgenic mice (Fig. 3b,c and Supplementary Fig. 4 ). Moreover, in response to TCR stimulation, apoptotic death of Tsc1 −/− Bcl2-transgenic cells was much less pronounced than that of Tsc1 −/− naive T cells (Fig. 3d,e ). These results demonstrate that the exacerbated death of Tsc1 −/− T cells is mediated by the intrinsic apoptotic pathway. The prosurvival function of Bcl-2 is dependent on its ability to antagonize the proapoptotic members of the Bcl-2 family. Among those, the Bcl-2 homology domain 3-only protein Bim is important in the initiation of lymphocyte apoptosis 1 . Naive Tsc1 −/− T cells had higher Bim expression, and after TCR stimulation, they retained high expression of Bim, whereas wild-type cells downregulated Bim expression ( Fig. 3f and Supplementary  Fig. 5a ). To determine whether Bim-dependent apoptosis accounted for the survival defect, we crossed Tsc1 −/− mice onto the Bim-deficient (Bcl2l11 −/− ) background. The frequency of CD8 + T cells in Tsc1 −/− Bcl2l11 −/− mice was over twofold greater than that of Tsc1 −/− mice ( Supplementary Fig. 5b ). Although the frequency of CD4 + T cells in Tsc1 −/− mice was not affected much by Bim deficiency in vivo, TCR-mediated apoptosis of Tsc1 −/ − Bcl2l11 −/− CD4 + T cells was less pronounced than that of Tsc1 −/− cells (Supplementary Fig. 5c ). Therefore, Bim-dependent and Bim-independent mechanisms trigger apoptosis when Tsc1 is absent.
We next assessed whether the survival defect of Tsc1 −/− T cells was associated with more production of reactive oxygen species (ROS), which have been linked to T cell apoptosis 27 . We found that Tsc1 −/− T cells had more ROS (Fig. 3g) . To assess whether the greater abundance of ROS in Tsc1 −/− T cells contributed to their extensive apoptosis, we used N-acetylcysteine, a widely used antioxidant. After treatment with N-acetylcysteine, the lower frequency of CD4 + T cells and CD8 + T cells in Tsc1 −/− mice was moderately restored (Supplementary Fig. 6a ). Consistent with those findings, the excessive TCR-mediated apoptosis of Tsc1 −/− T cells was partially suppressed for those from mice treated with N-acetylcysteine (Supplementary Fig. 6b ). Thus, both dysregulated proteins of the Bcl-2 family and more oxidative stress contribute to the apoptotic death of Tsc1 −/− cells.
Loss of quiescence and hyperactivation of Tsc1 −/− cells The homeostasis of naive T cells is believed to be contingent on the maintenance of a quiescent phenotype [4] [5] [6] . Freshly isolated Tsc1 −/− T cells were consistently larger (Fig. 4a) , which suggested that they probably underwent more cell growth. The cell-growth event precedes DNA synthesis and is a prerequisite for cell cycle entry 28 . We therefore assessed in vivo cycling of T cells by measuring incorporation of bromodeoxyuridine (BrdU). A greater percentage of Tsc1 −/− T cells than wild-type cells incorporated BrdU under steady-state conditions (Fig. 4b) , indicative of an exit from quiescence.
In the CD44 hi population, recently activated and memory-phenotype cells can be distinguished on the basis of expression of the IL-2 receptor β-chain (CD122) that is selectively expressed on memory-phenotype cells 6, 29 . In wild-type spleens, a large proportion of CD44 hi CD8 + T cells expressed CD122, but in Tsc1 −/− spleens, most CD44 hi CD8 + T cells were negative for CD122 expression (Fig. 4c) . The CD44 hi CD122 − CD4 + T cell population also expanded, although to a lesser extent (data not shown). In contrast, other T cell activation markers, including CD69, CD25 and CD5, were not altered by Tsc1 deficiency (data not shown). Tsc1 −/− T cells thus exist in a semiactivated state in vivo.
As Tsc1 −/− mice have a lymphopenic environment, it remained possible that the greater T cell activation was caused by homeostatic proliferation. To assess this possibility, we used the reconstituted bone marrow chimeras described above (Fig. 1e) to correct the lymphopenia. The larger total CD44 hi population observed in Tsc1 −/− mice was less pronounced in the mixed-bone marrow chimeras (Supplementary Fig. 7a ), which suggested that lymphopenia-induced population expansion contributed to this phenotype. In contrast, the A r t i c l e s CD44 hi CD122 − population was selectively expanded for donor cells derived from Tsc1 −/− bone marrow cells but not those from wildtype cells or the co-transferred CD45.1 + cells (Fig. 4d) . Moreover, Tsc1 −/− cells in the chimeras retained the features of larger cell size and more cycling ( Fig. 4e and Supplementary Fig. 7b) . Therefore, the semiactivated state in vivo was not driven mainly by the lymphopenic environment but was intrinsic to Tsc1 −/− T cells, which indicates a key role for Tsc1 in maintaining T cell quiescence. The loss of quiescence observed in Tsc1 −/− naive cells in vivo suggested that they may have a greater response to acute ex vivo TCR signals. To test this hypothesis, we stimulated naive Tsc1 −/− cells by TCR ligation and measured various parameters associated with T cell activation. Tsc1 −/− cells had larger cell size, more ROS production and more cell cycling than did wild-type cells (Fig. 4f,g ). Furthermore, upregulation of the activation markers CD25, CD69 and CD71 was more prominent in Tsc1 −/− cells (Fig. 4h) . Tsc1 deficiency thus promotes TCR-mediated activation of T cells.
Tsc1 establishes a quiescent gene-expression program
We next used functional genomics to analyze the Tsc1-dependent gene signature in naive T cells. Tsc1 −/− CD4 + T cells and CD8 + T cells had similar changes in expression profiles, with both having more upregulated genes than downregulated genes ( Supplementary  Fig. 8a ). For these Tsc1 target genes shared by CD4 + T cells and CD8 + T cells (Supplementary Table 1) , gene-ontology analysis showed that one of the groups with significant regulation by Tsc1 in naive T cells included genes encoding molecules involved in the cell-cycle pathway (P = 0.0000804). Naive Tsc1 −/− T cells had higher expression of positive regulators of the cell cycle, including cyclin A2, cyclin B2 and E2F2 (Supplementary Fig. 8b ), which would serve to synergistically promote cycling. To identify key networks regulated by Tsc1, we did gene-set enrichment analysis of naive Tsc1 −/− CD4 + T cells 30 . Tsc1 −/− T cells showed significant enrichment of 20 upregulated gene sets that included those encoding molecules involved in many metabolic pathways (nominal P value of 0). In addition, sets of genes encoding molecules involved in the cell-cycle and apoptotic pathways were also upregulated in naive Tsc1 −/− cells (Supplementary Fig. 8c) . Therefore, Tsc1 deficiency upregulates the metabolic and cell-cycle pathways.
We next determined the dynamics of the response of naive Tsc1 −/− T cells to TCR stimulation at the genome-wide level by comparing the gene-expression profiles of wild-type and Tsc1 −/− CD4 + T cells stimulated for 4 h with anti-CD3 and anti-CD28 (Supplementary Table 2 ). Gene-ontology analysis showed that stimulated Tsc1 −/− CD4 + T cells upregulated many genes encoding molecules associated with T cell activation, including cytokines and effector molecules (Ifng, Il4 and Gzma), cell surface molecules (Cd24a and Icam1), signaling molecules (Gadd45b and Gadd45g), transcription factors A r t i c l e s (Eomes, Myb and Bhlhe40) and cell cycle regulators. Conversely, genes known to be suppressed after TCR stimulation, especially Il7ra and S1pr1, were downregulated more profoundly in Tsc1 −/− cells (Fig. 5a) . Real-time PCR analysis confirmed the altered expression of Myb, Bhlhe40, Ifng, Gzma, Gadd45g and S1pr1 (Fig. 5b) . Thus, Tsc1 establishes a quiescence gene-expression program in T cells by linking cell-cycle and metabolic machineries and the expression of factors regulating the immune response.
Inducible deletion of Tsc1 abrogates T cell quiescence
To directly investigate the effects of Tsc1 on T cell quiescence, we crossed Tsc1 flox/flox mice with Rosa26-Cre-ER T2 mice (in which a gene encoding a fusion of Cre recombinase and the estrogen receptor T2 moiety (ER T2 ) is recombined into the ubiquitously expressed Rosa26 locus) to generate Tsc1 flox/flox Rosa26-Cre-ER T2 mice (called 'Tsc1-CreER mice' mice here). Tamoxifen-mediated inducible deletion of Tsc1 allowed us to exclude the contribution of potential secondary effects introduced by extensive T cell apoptosis, a lymphopenic environment or continuous loss of Tsc1 throughout the lifespan of the T cells. We treated wild-type and Tsc1-CreER mice with tamoxifen daily for a total of 4 d and then allowed them to 'rest' for 2 weeks. Tsc1 was efficiently deleted in T cells (data not shown), and this was associated with enlarged cells (Fig. 6a) and more rapid cycling in vivo (Fig. 6b) . After TCR stimulation, naive T cells from Tsc1-CreER mice had a larger cell size and more upregulation of CD25 expression than did control cells (Supplementary Fig. 9a,b) . Moreover, short-term deficiency in Tsc1 modestly affected the peripheral CD8 + T cell pool in vivo (Fig. 6c) . In response to ex vivo TCR signals, Tsc1-deficient T cells were more susceptible to apoptosis than were Tsc1-sufficient control cells (Fig. 6d) . More sustained loss of Tsc1, induced by tamoxifen treatment followed by 'rest' for 5 weeks, resulted in the loss of both CD4 + T cells and CD8 + T cells, as well as the development of a semi-activation phenotype in vivo ( Supplementary Fig. 9c-e) . Therefore, inducible deletion of Tsc1 in adult mice disrupts T cell quiescence.
Tsc1 enforces quiescence independently of cell survival
The results obtained by inducible deletion of Tsc1 suggested that Tsc1 deficiency abrogates T cell quiescence in the absence of overt apoptosis. To further explore the relationship between T cell quiescence and survival, we analyzed Tsc1 −/− mice expressing the Bcl2 transgene. Tsc1 −/− Bcl2-transgenic mice had a larger population of semiactivated (CD44 hi CD122 − ) T cells than did Bcl2-transgenic mice (Fig. 6e) . Also, Tsc1 −/− Bcl2-transgenic T cells were larger and showed more cycling (Fig. 6f,g ). After TCR stimulation, Tsc1 −/− Bcl2-transgenic cells retained the phenotype of larger cell size, more production of ROS and greater upregulation of activation markers relative to the control Bcl2-transgenic cells (Fig. 6h) . Therefore, the defective survival and quiescence in Tsc1 −/− cells were uncoupled after blockade of apoptosis. A r t i c l e s (Fig. 6a-d) , indicated that loss of quiescence is intrinsic to Tsc1 −/− T cells and apoptosis is probably a consequence.
Activation of mTORC1 disrupts immune homeostasis
We determined the biochemical mechanisms by which Tsc1 controls T cell homeostasis. We first measured the effects of Tsc1 deficiency on mTORC1 activity by examining phosphorylation of the kinase S6K1, the ribosomal protein S6 and 4E-BP1 (ref. 18) . Tsc1 −/− cells had more basal and TCR-induced activity of these conventional mTORC1 targets than did wild-type naive CD4 + T cells (Fig. 7a) , which indicated an inhibitory effect of Tsc1 on mTORC1 activity. We next measured mTORC2 activity by analyzing phosphorylation of Akt at Ser473 (ref. 18) . Tsc1 −/− T cells had less phosphorylation of Akt at Ser473 and of Foxo1 and Foxo3, two targets of mTORC2-Akt 18 (Fig. 7b) . We observed similar alterations in the activity of mTORC1 and mTORC2 in Tsc1 −/− CD8 + T cells (Supplementary Fig. 10a) . Notably, we also observed more mTORC1 activity in Tsc1 −/− CD4 + single-positive thymocytes (Supplementary Fig. 10b ) despite their lack of defects in survival or homeostasis. Thus, the physiological function of Tsc1 may be context dependent, with the effects influenced by the developmental stages of T cells or environmental cues received by T cells.
We next delineated the relative contributions of the two mTOR complexes to immune homeostasis. We administered the mTORC1 inhibitor rapamycin to wild-type and Tsc1 −/− mice for 3-5 d. As expected, rapamycin treatment resulted in less mTORC1 activity ( Supplementary  Fig. 11a ). Although such a short period of treatment was ineffective in affecting the peripheral T cell pool (Supplementary Fig. 11b) , rapamycin blocked the increase in size of Tsc1 −/− T cells (Fig. 7c) . After being transferred into wild-type recipient mice, rapamycintreated Tsc1 −/− naive T cells had substantially improved survival (Fig. 7d) . Furthermore, after TCR stimulation, these cells were mostly 'rescued' from the enhanced death and increase in size (Fig. 7e,f) . Therefore, the greater mTORC1 activity in Tsc1 −/− cells is needed to drive their excessive apoptosis and activation.
To assess the sufficiency and requirement of the diminished mTORC2-Akt activity in Tsc1 −/− T cells for immune homeostasis, we used two approaches. First, we analyzed mice deficient in Rictor, the loss of which abrogates mTORC2 activity 18 . Deletion of Rictor through the use of the Cd4-Cre system (Rictor −/− ) ablated phosphorylation of Akt at Ser473 and diminished phosphorylation of Foxo1 ( Supplementary  Fig. 12a) . Rictor −/− mice had a largely normal peripheral T cell pool, except for slightly fewer CD8 + T cells (data not shown), consistent with published reports 31, 32 . Deficiency in Rictor did not alter T cell size or responses to TCR, except that Rictor −/− CD8 + T cells had slightly more apoptosis in vitro (Supplementary Fig. 12b-d) . Therefore, loss of mTORC2 activity was insufficient to disrupt immune homeostasis. Second, to determine whether the diminished mTORC2-Akt activity was required for the Tsc1 −/− phenotype, we crossed Tsc1 −/− mice with those expressing an active transgene encoding Akt (Akt1) in T cells 33 . As expected, phosphorylation of the Akt target Foxo1 was largely restored in Tsc1 −/− Akt1-transgenic mice (Supplementary Fig. 13a) . However, the Akt1 transgene failed to rectify the disrupted T cell homeostasis and survival of Tsc1 −/− mice (Supplementary Fig. 13b-d) . Therefore, mTORC2 is neither necessary nor sufficient to abrogate A r t i c l e s the quiescence or survival of T cells. Although it remains possible that the impaired Akt activity might contribute to the greater sensitivity of Tsc1 −/− cells to apoptosis by accelerating the execution of cell death, ultimately it is not the driving force.
Having established a role for Tsc1 in T cell quiescence via mTORC1 inhibition, we next explored how the activity of the Tsc1 pathway is regulated. We first assessed whether Tsc2 expression was affected by deficiency in Tsc1, as these two molecules function as an integral complex 18 . Indeed, Tsc1 deficiency in T cells resulted in the loss of Tsc2 and thus ablation of the function of the entire Tsc1-Tsc2 complex (Supplementary Fig. 14a ). This finding, although not unexpected, allowed us to delineate how upstream signals were transduced to the complex by examining signal-induced Tsc2 phosphorylation 18 . Notably, Tsc2 activity can be positively or negatively regulated by phosphorylation at Ser1387 or Thr1462, respectively 18, 34, 35 . Phosphorylation of Tsc2 at Thr1462 was rapidly induced after T cell activation (Supplementary Fig. 14b ), which thereby relieved the inhibitory effects of the Tsc1-Tsc2 complex on mTORC1 activity. Conversely, naive T cells maintained considerable phosphorylation of Tsc2 at Ser1387, but this diminished after sustained TCR stimulation (Supplementary Fig. 14b) . These results support a model in which the Tsc1-Tsc2 complex is inactivated by TCR signals to facilitate mTORC1 activation, but the complex function is maintained in naive T cells to keep mTORC1 in check.
Tsc1 regulates antigen-specific immune response in vivo
To investigate the roles of Tsc1 in T cell-mediated immune response in vivo, we infected wild-type and Tsc1 −/− mice with recombinant Listeria monocytogenes expressing ovalbumin (OVA). CD8 + T cells from infected Tsc1 −/− mice had significantly fewer tetramerpositive, antigen-reactive cells than did those from infected wild-type control mice (Fig. 8a,b) . Tsc1 −/− mice also had fewer interferon-γ-producing CD8 + T cells after ex vivo restimulation with OVA peptide (amino acids 257-264; Fig. 8c,d ). These findings demonstrated that Tsc1 is required for the antigen-specific immune response in vivo.
Given the excessive apoptosis of Tsc1 −/− T cells, we determined whether the requirement for Tsc1 in the immune response was due to its effect on cell survival. For this, we analyzed the antibacterial immune response of Tsc1 −/− Bcl2-transgenic mice, which had mostly normal T cell numbers (Fig. 3b,c) . The population expansion of OVA-reactive CD8 + T cells was impaired in these mice ( Fig. 8 and Supplementary Fig. 15a) , despite a similar extent of apoptosis in the OVA-reactive cells from Tsc1 −/− Bcl2-transgenic mice and Bcl2-transgenic mice (Supplementary Fig. 15b) . Thus, the effect of Tsc1 in promoting immune responses can be largely separated from its role in T cell survival. We then examined whether Tsc1 deficiency was associated with an intrinsic defect in the differentiation into effector T cells. Under optimal differentiation conditions in vitro, naive CD8 + T cells from Tsc1 −/− Bcl2-transgenic cells were able to differentiate into interferon-γ-positive cells (with slightly higher interferon-γ expression on a per-cell basis than that of Bcl2-transgenic control cells; Supplementary Fig. 15c ). Deficiency in Tsc1 therefore dampens in vivo immune responses through a mechanism largely independent of T cell survival or intrinsic differentiation potential. A r t i c l e s DISCUSSION A longstanding question in immunology is how the quiescence of naive T cells is established 4, 5 . Here we have reported that Tsc1-dependent control of mTOR activity was critical in enforcing the quiescence of naive cells. Loss of this control mechanism in Tsc1 −/− T cells resulted in larger cell size, rapid cycling and exuberant TCR activation that predisposed these cells to apoptotic cell death, which establishes Tsc1 as an intrinsic factor in maintaining T cell quiescence. Furthermore, Tsc1 was important for an antigen-specific immune response, a function largely independent of Tsc1-mediated survival effects. At the molecular level, Tsc1 acted as part of the Tsc1-Tsc2 complex, whose activity was dynamically regulated by TCR signals. Tsc1 enforced T cell homeostasis by controlling mTORC1 activity to suppress the metabolic and cell-cycle machineries and to establish a quiescent gene-expression program. We propose that a Tsc1-dependent pathway acts as a key checkpoint in naive T cells by integrating extracellular signals to control mTOR activity, thereby coordinating the quiescence, survival and immune function of T cells. Deficiency in Tsc1 in T cells led to exit from quiescence and excessive apoptosis. We observed both effects in vivo under lymphopenic and lymphoreplete conditions, and these were further recapitulated in highly purified naive T cells in vitro. Are these two effects independent of each other or causally linked? Tsc1 −/− T cells relied partly on Bim-dependent and oxidative-stress pathways to trigger apoptosis. Furthermore, they were protected from death by the Bcl2 transgene, yet these T cells retained the phenotype of disrupted quiescence, as shown by the population expansion of semiactivated T cells and greater cell size and enhanced cycling and response to TCR signals. In contrast, short-term treatment with rapamycin diminished cell size and TCR activation and, more notably, restored the resistance of Tsc1 −/− cells to apoptosis. Therefore, the failure of Tsc1 −/− naive T cells to engage the survival machinery stemmed from loss of quiescence, an idea further supported by transcript profiling and analysis of T cells after inducible deletion of Tsc1. We conclude that Tsc1 actively maintains a quiescence program in naive T cells that renders them resistant to apoptosis. Notably, Tsc1 regulates the production of innate cytokines 36 , and Tsc1 deficiency in hematopoietic stem cells results in rapid cycling and population expansion but impaired hematopoiesis and self-renewal 37, 38 . In the thymus, whereas Tsc1 regulated mTOR activity, we noticed no survival defects in Tsc1 −/− thymocytes. Indeed, except for under nonphysiological conditions such as nutrient starvation and genome damage 39, 40 , mTOR activity is generally thought to promote cell growth and survival in diverse cellular contexts 18 . In T cells, inhibition of mTOR by rapamycin in vitro results in smaller cell size but not impaired survival 41 . Therefore, Tsc1 has a previously unappreciated role in naive T cells in linking their quiescence and survival, whereas after TCR ligation, the activity of the Tsc1-Tsc2 complex is downregulated to facilitate T cell activation.
An equally unexpected finding was that Tsc1-deficient T cells failed to mount an efficient antigen-specific immune response in vivo despite their enhanced response to acute TCR stimulation. We observed this effect even when the excessive apoptosis of Tsc1 −/− T cells was largely blocked, which suggests that maintenance of naive T cell quiescence is important for a productive immune response. The precise mechanism by which Tsc1 deficiency dampens the immune response is uncertain but may involve premature activation of the cell-cycle and metabolic machineries and transcriptional responses in Tsc1 −/− naive cells before they receive proper TCR signals. Although blocking mTOR activity blunts effector T cell differentiation 20 , our results indicated that hyperactive mTORC1 was also detrimental to antigen-specific responses. These findings highlight the presence of a defined threshold of mTOR activity in naive T cells to engage a productive immune reaction. Notably, mTOR inhibits the development of memory CD8 + T cells [42] [43] [44] . From a metabolic perspective, both naive and memory cells are quiescent 17 . We speculate that maintenance of a quiescent state is essential for the strength of immune responses mediated by both naive and memory T cells; further study is needed to test this.
Work on mTOR signaling in the adaptive immune system has centered on its effects on T cell differentiation 20 . Studies have shown that mTOR promotes the generation of effector cells while inhibiting the differentiation of regulatory T cells 26, 31, 32, 45, 46 . None of the reported mouse strains with mutations in genes encoding components of the mTOR pathway have the phenotype of defective T cell quiescence or survival. To our knowledge, the genetic model with the most extensive similarity to Tsc1 −/− mice is electra, an immunodeficient mouse line carrying a mutation in the gene encoding Schlafen-2, a protein with no distinct biochemical function 6 . We also noted that Tsc1 −/− mice had considerably fewer memory-phenotype (CD44 hi CD122 + ) cells, a defect resistant to Bcl-2-mediated 'rescue' . Therefore, the differentiation of Tsc1 −/− cells into memory cells was probably blocked, 
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-/-Bcl2-TG consistent with the effects of rapamycin on the promotion of memory development [42] [43] [44] . In contrast, the loss of iNKT cells in Tsc1 −/− mice resulted from impaired survival, as the Bcl2 transgene 'rescued' this defect. Tsc1 therefore controls the homeostasis of different T cell populations via distinct mechanisms. Persistent activation of mTOR results in metabolic stress and is associated with diverse pathologies such as cancer and metabolic diseases 18 . Conversely, inhibition of mTOR by rapamycin prolongs the lifespan and improves quality of life by diminishing the incidence of age-related pathologies in various species, ranging from worms and fruit flies to mammals 47 . As a parallel, aberrant mTOR activity due to the functional loss of Tsc1 in T cells resulted in exit from quiescence and exacerbated activation and apoptosis, which were ameliorated by rapamycin treatment. Therefore, the adaptive immune system has evolved to adopt an evolutionarily conserved pathway to regulate the lifespan and function of naive T cells.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
